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Recent studies in rodents convincingly demonstrated that PPARα is a key regulator of genes involved in carnitine homeostasis,
which serves as a reasonable explanation for the phenomenon that energy deprivation and fibrate treatment, both of which cause
activation of hepatic PPARα, causes a strong increase of hepatic carnitine concentration in rats. The present paper aimed to
comprehensively analyse available data from genetic and animal studies with mice, rats, pigs, cows, and laying hens and from
human studies in order to compare the regulation of genes involved in carnitine homeostasis by PPARα across diﬀerent species.
Overall, our comparative analysis indicates that the role of PPARα as a regulator of carnitine homeostasis is well conserved across
diﬀerent species. However, despite demonstrating a well-conserved role of PPARα as a key regulator of carnitine homeostasis
in general, our comprehensive analysis shows that this assumption particularly applies to the regulation by PPARα of carnitine
uptake which is obviously highly conserved across species, whereas regulation by PPARα of carnitine biosynthesis appears less well
conserved across species.
1. Introduction
Peroxisome proliferator-activated receptor α (PPARα) is
considered a master transcriptional regulator of lipid
metabolism and energy homeostasis [1], because typical
genes regulated by PPARα are involved in all aspects of
fatty acid catabolism (cellular fatty acid uptake, activation
of fatty acids, intracellular fatty acid transport, import of
fatty acids into the mitochondria, and mitochondrial and
peroxisomal fatty acid β-oxidation), ketogenesis, as well as
gluconeogenesis [2]. PPARα-dependent gene transcription is
initiated when a ligand, for example, fatty acids which are
released from white adipose tissue during energy deprivation
and taken up into tissues during this state, or exogenous
ligands such as fibrates (WY-14,643, clofibrate, fenofibrate,
bezafibrate, and gemfibrozil), binds to the ligand-binding
domain of this transcription factor. Mechanistic details of
gene regulation by PPARα and tissue distribution of PPARα
has been extensively described in the literature, wherefore
the reader is referred to the literature with regard to this
[3]. Interestingly, earlier studies repeatedly reported that
energy deprivation or treatment of rats with fibrates causes
a marked, up to 5-fold elevation of the hepatic concentration
of carnitine [4–7]. The molecular mechanisms underlying
this phenomenon, however, have not been resolved from
these studies. It was not until about twenty years later that
activation of hepatic PPARα, which is common to energy
deprivation and fibrate treatment, was shown to cause an
increase in the expression of genes involved in carnitine
uptake and biosynthesis in liver cells [8] serving as a reason-
able explanation for the abovementioned phenomenon. In
subsequent studies it was shown that elevation of hepatic car-
nitine concentration in response to fasting, or fibrates occurs
only in wild-type mice but not in transgenic mice lacking a
functional PPARα protein strengthening the assumption that
PPARα is a critical regulator of carnitine homeostasis [9, 10].
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Using more sophisticated molecular biological techniques it
could be convincingly demonstrated that the mouse genes
encoding the carnitine transporter novel organic cation
transporter 2 (OCTN2/SLC22A5) and two enzymes of the
carnitine biosynthetic pathway, γ-butyrobetaine dioxygenase
(BBOX1) and 4-trimethylaminobutyraldehyde dehydroge-
nase (ALDH9A1), are direct PPARα target genes as evidenced
by the identification of functional PPRE within the regula-
tory region of the respective genes [11–13].
It is well established that PPARα activators exert dis-
tinct species-specific actions [14–17]. In rodents, like mice
and rats, administration of PPARα activators leads to a
marked peroxisomal enzyme induction, peroxisome prolif-
eration, and even hepatocarcinogenesis [18, 19]. In contrast,
PPARα activators cannot induce peroxisome proliferation
and hepatocarcinogenesis and the induction of peroxisomal
metabolism pathways is much less pronounced in human
hepatocytes and livers from nonhuman primates [17]. This
distinct response of the peroxisomes to PPARα activators
is responsible for the classification of diﬀerent species
into proliferating (mice, rats) and nonproliferating ones
(humans, monkeys, guinea pigs). Several factors are consid-
ered to account for the marked diﬀerence in the response
to PPARα activators between diﬀerent species: expression
level of PPARα, degree of conservation and functionality
of the PPRE in the regulatory region of target genes, and
lack or overexpression of transcriptional coregulators [17].
Apart from these marked diﬀerential eﬀects of PPARα
activators on peroxisome proliferation between proliferating
and nonproliferating species, a comparative analysis of gene
regulation by PPARα between mouse and human revealed
that at least the role of PPARα as a master regulator of
hepatic lipid catabolism is well conserved [20]. It may be
therefore expected that regulation of carnitine homeostasis,
which is intrinsically linked to fatty acid catabolism because
the transport of fatty acids from the cytosol into the
mitochondrial matrix for subsequent fatty acid β-oxidation
is carnitine-dependent, is also a well conserved function of
PPARα. However, despite its well conserved role as an impor-
tant regulator of lipid catabolism in general, the specific
genes under control of PPARα within each lipid metabolic
pathway were shown to diﬀer at least between humans and
mice [20]. Thus, whether PPARα can be considered as a
critical regulator of genes involved in carnitine homeostasis
across diﬀerent species requires thorough analysis of the
eﬀect of PPARα activation on carnitine homeostasis in each
individual species and cannot be predicted for one species by
simply transferring observations obtained in mice or rats. In
light of the abovementioned species specificities with regard
to the response to PPARα activation the present paper aims
to (1) briefly describe current knowledge about the genes
involved in the regulation of carnitine homeostasis and (2)
to comprehensively analyse available data from genetic and
animal studies with mice, rats, pigs, cows, and laying hens
and from human studies in order to compare the regulation
of genes involved in carnitine homeostasis by PPARα across
diﬀerent species.
2. Regulation of Carnitine Homeostasis
Carnitine is a water soluble quaternary amine (3-hydroxy-
4-N,N,N-trimethylaminobutyric acid) which is essential for
normal function of all tissues. The primary function of
carnitine is to facilitate the translocation of activated long-
chain fatty acids from the cytosol into the mitochondrial
matrix, a process called carnitine shuttle, for subsequent
fatty acid β-oxidation. In mammals, carnitine is considered
a conditionally essential nutrient because it is synthesized by
the organism but most is taken up from the diet [21]. Food
of animal origin, such asmeat and dairy products, containing
high carnitine levels, makes the greatest contribution to total
carnitine uptake. In contrast, the intake of food of plant
origin is negligible for dietary carnitine uptake due to its very
low carnitine levels [22]. Thus, dietary uptake of carnitine
in strict vegetarians is very low and has been estimated
to be less than 0.02mg per kg body weight and day [23],
whereas dietary carnitine uptake through an omnivorous
diet provides approximately 0.3–1.9mg carnitine per kg
body weight and day. Nonetheless, plasma carnitine levels in
vegetarians are only 15–30% lower than those in nonvege-
tarians, being yet within the normal physiological range (25–
50 μmol/L), because vegetarians have a more eﬃcient renal
reabsorption of carnitine (urinary total carnitine excretion
was 55% less in vegetarians than in nonvegetarians [24])
and a greater rate of endogenous carnitine biosynthesis
[25, 26]. In healthy vegetarians, carnitine deficiency (plasma
carnitine concentration < 25 μmol/L [26]) may develop only
if certain micronutrients, such as vitamin C, vitamin B6,
and iron, which are required as co-factors for carnitine
biosynthesis are not provided from the diet in suﬃcient
amounts. The tubular reabsorption of carnitine in the
kidney, where >95% of filtered free carnitine is reabsorbed
when plasma free carnitine concentration is within the
normal range, is of great importance for maintaining normal
plasma carnitine levels. This is evidenced by the fact that
patients with inborn or acquired defects in this tubular
carnitine reabsorption process develop primary systemic
carnitine deficiency with markedly reduced serum carnitine
levels (0–5 μmol/L) because most of the filtered carnitine
is lost in the urine [27]. If plasma carnitine concentration
exceeds the normal range (supraphysiologic levels) due to
the uptake of high dosages of carnitine (e.g., oral or i.v.
supplementation), the excess carnitine is rapidly eliminated
due to saturation of the tubular reabsorption mechanism
[26, 28]. This explains the fact that the ability to maintain
supra-physiologic plasma carnitine concentrations is limited
[29, 30]. The skeletal muscle contains the majority of the
total body carnitine [31], and, like the myocardium, is
dependent on the active uptake of carnitine from plasma
against a strong concentration gradient (from 25–50 μmol/L
in plasma to about 4000 μmol/L in skeletal muscle) [32]. Due
to this large endogenous carnitine pool, a single intravenous
dose of carnitine or short-term oral supplementation with
carnitine at high doses (4–6 g/day) has little or no impact on
the muscle carnitine content [33–35].
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3. Genes Encoding Proteins Involved in
Carnitine Homeostasis
3.1. Carnitine Biosynthesis. The carnitine biosynthesis path-
way consists of a cascade of four distinct enzymatic reactions
through which 6-N-trimethyllysine (TML), which is the
substrate for carnitine biosynthesis, is converted stepwise
into carnitine. TML is the product of lysosomal and pro-
teasomal degradation of proteins containing N-methylated
lysines, such as calmodulin, myosin, actin, and histones
[21]. In the first enzymatic step, TML is hydroxylated by
the enzyme TML dioxygenase (encoded by TMLHE) to
yield 3-hydroxy-TML (HTML). Subsequently, the second
enzyme, called HTML aldolase (encoded by HTMLA),
catalyzes an aldolytic cleavage of HTML, which results in
the formation of 4-trimethylaminobutyraldehyde (TMABA).
The third enzyme, called TMABA dehydrogenase (encoded
by ALDH9A1), catalyzes the dehydrogenation of TMABA
to 4-N-trimethylaminobutyrate or γ-butyrobetaine (BB).
In the final biosynthetic step, BB is hydroxylated by BB
dioxygenase (encoded by BBOX1) to form carnitine [21].
In all mammals, a significant BBD activity is found in the
liver [36], and in some species such as in humans, pigs,
cats, cows, hamsters, rabbits, or Rhesus monkeys also in the
kidney [36, 37]. Other tissues than liver and kidney have
either no or only a very low activity of BBD [36, 37], and
are therefore highly dependent on active carnitine uptake
from blood. The BB, which is formed in extrahepatic tissues,
is excreted and transported via the circulation to the liver,
where it is converted into carnitine [36].
3.2. Carnitine Uptake. Tissues which are incapable of pro-
viding carnitine via endogenous biosynthesis, such as skeletal
muscle andmyocardium, are highly dependent on the uptake
of carnitine from the circulation. This transport across the
plasma membrane against a high concentration gradient
(in skeletal muscle > 100-fold) is mediated by the novel
organic cation transporters (OCTNs) which belong to the
solute carrier 22A family [38, 39]. The OCTN2 isoform,
which is sodium-dependent and high-aﬃnity, is considered
the physiologically most important one due to its wide
tissue expression [40, 41]. This transporter represents the
molecular basis for the tubular reabsorption process of
carnitine in the kidney and is therefore fundamental for
maintaining normal carnitine levels in serum. As mentioned
above, defects in the renal reabsorption process of carnitine
due to a mutation in the OCTN2 gene are causative for
severe carnitine deficiency in such patients [42]. In the small
intestine, OCTN2 also plays a key role for the absorption of
carnitine from the diet [43]. This is based on the observation
that in mice with a genetic defect in the OCTN2 gene oral
bioavailability of carnitine was reduced by approximately
50% [44].
The OCTN1 isoform is considered to contribute less to
carnitine transport than OCTN2 due to its low carnitine
transport activity. OCTN1 is localized in the mitochondrial
membrane in close proximity to CPT I, the rate-limiting
enzyme for carnitine-dependent fatty acid oxidation. Due
to this localization, OCTN1 has been proposed to oper-
ate on the mitochondrial influx and eﬄux of carnitine
and acylcarnitine esters indicating that OCTN1 is mainly
involved in maintaining intracellular carnitine homeostasis
[45]. Another OCTN isoform, namely, OCTN3, has been
suggested to play a role for carnitine uptake into testis and
to also mediate renal reabsorption of carnitine [41].
4. Evidence for a Role of PPARα in
Regulating Genes Involved in
Carnitine Homeostasis in Different Species
4.1. Rat. Based on earlier reports that energy deprivation
or treatment with fibrates, both of which induce activation
of hepatic PPARα, causes a marked elevation of the hepatic
carnitine concentration [4–7], we have recently tested the
hypothesis that PPARα activation is responsible for this
phenomenon. Indeed, we demonstrated for the first time
that PPARα activators strongly increase transcript levels
of OCTN2 in rat liver and cultivated rat hepatocytes [8].
Moreover, we found that the increase in OCTN2 mRNA
abundance in response to treatment with PPARα activa-
tors was accompanied by an elevation of the carnitine
concentration in rat liver and cultivated rat hepatocytes
[8]. These findings provided the first evidence that PPARα
plays a role in regulating carnitine homeostasis through
stimulating OCTN2-mediated carnitine uptake from blood
into the liver. In subsequent studies with rats, we found
that treatment with PPARα activators increases also OCTN2
transcript levels in small intestine [46, 47], and improves
intestinal carnitine absorption [47]. Thus, these observations
confirmed our assumption that PPARα is an important
regulator of carnitine uptake and that upregulation of
OCTN2 in small intestine may contribute to the elevation
of hepatic carnitine concentration in response to PPARα
activators through increasing carnitine availability from the
diet. A further study in rats revealed that energy deprivation,
which is a physiologic state of PPARα activation, also
results in increases of OCTN2 transcript levels and carnitine
concentration in the liver [48]. Since administration of
oxidized fats causes a strong activation of PPARα in rats
[49–51] due to the high content of hydroxylated fatty acids
and cyclic fatty acid monomers, both of which are ligands
of PPARα, we also investigated whether feeding of oxidized
fats causes similar eﬀects on carnitine homeostasis as energy
deprivation and fibrate treatment [52]. Indeed, we observed
that administration of oxidized fat for 6 d causes an elevation
of OCTN2 transcript levels in liver and small intestine and
increases hepatic carnitine concentration of rats indicating
that carnitine homeostasis is regulated also by nutritive
PPARα activators.
Since the results from these experiments suggested that
OCTN2 might be a direct target gene of PPARα, we
performed in silico analysis of the rat OCTN2 promoter
which revealed several putative PPRE upstream of the
transcription start site [46]. Using reporter gene and gel
mobility shift assays, Maeda et al. [53] recently identified one
functional PPRE in the rat OCTN2 promoter confirming our
4 PPAR Research
assumption that the rat OCTN2 gene is a direct PPARα target
gene. However, in comparison to the marked induction of
OCTN2 mRNA by fibrates and fasting [8, 46, 48] the weak
stimulation of rat OCTN2 promoter activity reported from
Maeda et al. [53] suggested that a more potent PPRE, located
in other regulatory regions than the proximal promoter,
might be responsible for OCTN2 upregulation in response
to PPARα activation.
Although previous studies in rats indicated that the
clofibrate-induced increase in hepatic carnitine concentra-
tion is due to an increase in the rate of hepatic carnitine
synthesis [6, 7], results from analysis of gene expression of
enzymes of the carnitine biosynthesis pathway in rats do not
point towards a role for PPARα in regulating genes involved
in carnitine biosynthesis in rats. All of the abovementioned
studies in rats did not show any increase in the transcript
levels of ALDH9A1 and BBOX1 in the liver in response
to fibrate treatment, fasting, or administration of oxidized
fat. This indicates that at least the rat genes encoding
ALDH9A1 and BBOX1 are not transcriptionally regulated
by PPARα, despite the fact that several conserved PPRE
were identified in the proximal promoter of the rat BBOX1
gene using NUBIScan software [9]. However, studies in rats
demonstrated that both clofibrate and fasting increase the
concentration of the carnitine precursor TML in the liver
[46, 48, 54]. Since carnitine biosynthesis starts with the
enzymatic conversion of TML, the availability of TML has
been considered to be rate limiting for carnitine biosynthesis
[55]. In fact, TML is subsequently converted into BB, which
itself is rapidly further converted into carnitine due to the
large capacity of the liver to convert BB into carnitine [56].
Thus, it is possible that carnitine biosynthesis is stimulated by
PPARα activation, an eﬀect that is notmediated by increasing
expression of genes encoding enzymes of the carnitine
biosynthesis pathway but rather by stimulating lysosomal
and proteasomal degradation of proteins which leads to the
release of TML [57, 58]. The observation that both clofibrate
and fasting stimulate proteolysis [59] is supportive for this
assumption.
4.2. Mouse. According to convincing data from studies with
rats that PPARα plays a role in the regulation of carnitine
homeostasis, studies with PPARα knockout and correspond-
ing wild-type mice have been conducted [9, 10]. van Vlies
et al. [9] were the first demonstrating that PPARα regulates
gene expression of OCTN2 in the liver of mice as evidenced
by the observation that upregulation of OCTN2 in response
to fasting or WY-14,643 treatment occurs only in wild-type
but not in PPARα knockout mice. Using the same mice
genotypes, Koch et al. [10] largely confirmed these findings
from van Vlies et al. [9] but additionally demonstrated that
PPARα activators cause OCTN2 upregulation also in kidney
and small intestine. Studies from both groups showed that
the elevation of hepatic carnitine concentration in response
to PPARα activation occurs only in wild-type mice [9, 10],
which provided further evidence that PPARα is a critical
player for regulating carnitine homeostasis. Noteworthy,
these studies revealed also upregulation of genes encoding
the carnitine biosynthetic enzymes ALDH9A1 and BBOX1
in the liver of wild-type but not PPARα knockout mice
indicating that genes involved in carnitine biosynthesis are
regulated by PPARα in mice, which is in contrast to the rat.
Further indication for the PPARα dependency of regula-
tion of the mouse genes encoding OCTN2, ALDH9A1, and
BBOX1 is provided by the observation that hepatic mRNA,
and protein levels of OCTN2, ALDH9A1, and BBOX1 are
decreased in obese mice compared to lean mice [60], because
high fat diet-induced obesity was reported to disrupt hepatic
PPARα function and to impair PPARα dependent gene
transcription [61, 62]. Noteworthy, this study showed that
the reduced hepatic expression levels of OCTN2, ALDH9A1,
and BBOX1 were partially restored to expression levels of
lean mice in a subgroup of the obese mice which were
regularly exercised on a motorized treadmill (35min, 5 x/wk,
10wk). Since endurance exercise causes activation of PPARα,
these data suggest that endurance exercise was able to
restore at least in part the obesity-induced disruption of
PPARα function and thereby contributed to the elevated gene
expression of OCTN2, ALDH9A1, and BBOX1.
Besides direct transcriptional regulation of genes
involved in carnitine homeostasis by PPARα, evidence
has been provided that PPARα might influence the
availability of requisite biosynthetic precursors—through
the abovementioned stimulatory eﬀect of PPARα activation
on proteolysis—and enzymatic cofactors required for
carnitine synthesis. In this context a study from Makowski
et al. [63] is worth mentioning which reported that PPARα
knockout mice display markedly lower levels of methionine,
which serves as a methyl donor during posttranslational
assembly of methylated proteins, and α-ketoglutarate, which
is a cofactor of TMLHE and BBOX1, in plasma and tissues,
respectively, than wild-type mice.
Recent molecular biological studies by our own group
revealed that the mouse genes encoding OCTN2, BBOX1,
and ALDH9A1 are direct PPARα target genes [11–13], which
is in line with the abovementioned observations from studies
with PPARα knockoutmice [9, 10]. Direct regulation of these
genes by PPARα was evidenced by the identification of one
functional PPRE each in the regulatory region of these genes.
The functional PPREs were shown to be located in either the
proximal promoter (BBOX1 and ALDH9A1; [12, 13]) or the
first intron (OCTN2; [11]). Taken together, these findings
confirm that PPARα plays a key role in the regulation of
carnitine homeostasis in the mouse by controlling genes
involved in carnitine synthesis and carnitine uptake.
4.3. Pig. The abovementioned observations in rodents can-
not be directly applied for humans, because of marked
diﬀerences in the response to PPARα activators between
rodents and humans [17, 18]. In contrast to rodents, pigs
have a low expression of PPARα in the liver and the response
to PPARα activators (induction of peroxisomal metabolism
pathways, peroxisome proliferation) is very weak, wherefore
pigs like humans and nonhuman primates belong to the
nonproliferating species. A recent study from our group
showed that PPARαmRNA levels in the liver are comparable
between pig and human [64], which suggests that the pig
is a suitable model for humans to study the eﬀects of
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PPARα activation. Activation of PPARα in liver and other
tissues of pigs have been already demonstrated in response
to clofibrate, oxidized fat as well as fasting [65–67]. In
order to study whether carnitine homeostasis is regulated by
PPARα also in pigs we performed two experiments in which
pigs were either treated with clofibrate or fasted for 24 h.
Treatment with clofibrate caused an upregulation of OCTN2
in liver, skeletal muscle, and small intestine, and increased
carnitine concentrations in liver and skeletal muscle [68].
Upregulation of OCTN2 in the liver and elevated carnitine
concentrations in liver and kidney were also found in pigs
which were fasted for a period of 24 h [67]. In the latter
study, fasting was also shown to increase BBOX1 mRNA
level and BBOX1 activity in liver and kidney [67]. Thus,
these observations from studies with pigs indicate that
carnitine homeostasis in pigs is also regulated by PPARα,
even though the extent of upregulation of OCTN2 and
BBOX1 is lower in pigs than in rodents. The latter may be
explained by the lower tissue expression level of PPARα in
pigs than in rodents but also by species diﬀerences in the
availability of transcriptional coregulators. In this context it
is worth mentioning that a large number of PPAR related
coregulators, such as CBP/p300, SRC-1-3, PGC-1α, PGC-
1β, PRIP, PRIC285, CARM1, and PIMT, have been described
to influence PPAR target gene transcription and that their
relative availability in a given tissue is at least partially
responsible for the tissue specific expression of target genes
and the responsiveness of PPAR isotypes to specific ligands
[69].
4.4. Cattle. In contrast to the large body of literature with
regard to the regulation of carnitine homeostasis by PPARα
in rodents, only limited information is available on the
regulation of PPARα activity and its role for carnitine
homeostasis in cattle liver. Apart from demonstrating that
PPARα is functional in cattle liver [70] and long-chain fatty
acids are able to activate PPARα in bovine cells [71, 72],
it was shown that the negative energy balance occurring in
early lactating dairy cows is associated with an upregulation
of several established PPARα target genes in nonruminants
in the liver being indicative of PPARα activation during
early lactation [73–76]. Based on previous observations that
hepatic carnitine concentration in dairy cows is increasing
during the transition from late pregnancy to early lactation
[77, 78], we have recently investigated whether hepatic
genes of carnitine synthesis and uptake of carnitine are
upregulated during early lactation in dairy cows [79]. As
expected and in accordance with results from a recent study
[73], our study showed that the negative energy balance
occurring at early lactation was associated with elevated
plasma levels of free fatty acids and increased transcript
levels of established PPARα target genes in nonruminants
[79], which is indicative of activation of hepatic PPARα
in early lactating cows. In line with our hypothesis, our
study showed that the transition from late pregnancy (3wk
prepartum) to early lactation leads to an upregulation of
various genes involved in carnitine synthesis (ALDH9A1,
TMLHE, BBOX1) and carnitine uptake (OCTN2) in the
liver of cows at 1 wk postpartum [79]; transcript levels of
TMLHE, ALDH9A1, BBOX1, and OCTN2 were 10-, 6-, 1.8-,
and 13-fold, respectively, higher in the liver of dairy cows
at 1 wk postpartum than at 3wk prepartum. In addition,
concentration of carnitine in the liver was increased from
3wk prepartum to 1wk postpartum. In contrast, from 1wk
to 5 and 14wk postpartum transcript levels of TMLHE,
ALDH9A1, BBOX1, and OCTN2 and hepatic carnitine
concentrations were declining [79]. Thus, it is likely that the
observed changes in the expression of these genes account
for the alterations of hepatic carnitine concentration during
the transition period and the lactation cycle. Noteworthy,
we also found that plasma concentrations of free fatty acids
and hepatic carnitine concentrations at 1 wk, 5 wk, and
14wk postpartum were positively correlated. Although it
remains to be established that the bovine genes encoding
TMLHE, ALDH9A1, BBOX1, and OCTN2 are direct PPARα
target genes, the positive correlations between plasma free
fatty acids, which are endogenous activators of PPARα,
and hepatic carnitine concentrations during lactation are
supportive for a role of PPARα in the regulation of carnitine
homeostasis in cattle. Besides these data from pregnant and
lactating cows which provide indirect evidence for a PPARα-
dependency of carnitine homeostasis in cattle, unpublished
data from our own group from cell culture experiments
provide stronger evidence for a role for PPARα in regulating
genes involved in carnitine homeostasis in cattle. We found
that treatment of bovine kidney cells with a PPARα agonist
increases transcript and protein levels of OCTN2. Whether
the bovine BBOX1 gene is also regulated by PPARα cannot
be answered with certainty because BBOX1 is not expressed
in this bovine kidney cell line (unpublished observation).
4.5. Chicken. Like in mammals, PPARα has been shown to
be highly expressed in chicken liver and to play an important
role for the homeostasis of energy and lipid metabolism
during fasting [80]. In addition, a high homology of avian
PPARα with mouse, rat, and human PPARα [81, 82] and
a similar expression pattern of PPARα in tissues between
chicken and rodents as well as humans has been reported
[81, 82]. Moreover, a recent study demonstrated that PPARα
in the liver of laying hens can be strongly activated by
the administration of clofibrate as evidenced from elevated
transcript levels of classical PPARα target genes [83]. In order
to study the regulation of carnitine homeostasis by PPARα in
laying hens, we have recently performed a study with laying
hens which were fed diets supplemented without (control)
or with clofibrate [84]. Interestingly, this study revealed that
treatment with clofibrate increased carnitine concentration
not only in the liver but also in the whole egg, yolk, and
albumen. On the molecular level, activation of PPARα in
the liver of clofibrate-treated hens could be demonstrated
by elevated transcript levels of classical PPARα target genes.
In addition, this study demonstrated that OCTN2 but not
genes encoding enzymes of carnitine biosynthesis in the
liver are upregulated by clofibrate in the liver of laying hens
[84], which indicates that increased carnitine concentrations
in the liver of hens treated with clofibrate might be due
to stimulation of OCTN2-mediated carnitine uptake from
plasma into liver cells. Thus, the findings from this study
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suggested that PPARα has an essential role in the regulation
of carnitine homeostasis in hens like in mammalian species.
Unlike in mice and pigs, however, PPARα in laying hens
appears to play a role only for regulating OCTN2-mediated
carnitine uptake but not carnitine biosynthesis. In a further
study, it has been investigated whether carnitine homeostasis
in laying hens can be also influenced by the administration
of nutritive PPARα activators [85]. This study however
failed to demonstrate an influence of either fish oil or
conjugated linoleic acid (CLA) on carnitine homeostasis in
laying hens. The lack of eﬀect of nutritive PPARα agonists
on carnitine homeostasis, however, is not a contradiction to
the abovementioned study but rather reflects the fact that
activation of PPARα by both fish oil and CLA in this study
was negligible, which itself is likely due to the low binding
aﬃnity of n-3 PUFA and CLA isomers when compared to
the synthetic PPARα activator clofibrate.
4.6. Human. In contrast to extensive research on the regu-
lation of carnitine homeostasis by PPARα in animals, only
few studies with limited significance are available to evaluate
whether PPARα regulates carnitine homeostasis in humans
as well. One important reason for the limited significance
of human studies is that, with few exceptions, most of them
used plasma samples only, which is not appropriate for eval-
uating changes in carnitine homeostasis. To our knowledge
only one study is available in the literature analyzing the
change in the urinary profile of carnitine and its derivates
in healthy adults in response to starvation [86], which is
the physiological state of PPARα activation. According to
this study, 48 h starvation caused a slight decrease in the
urinary excretion of free carnitine and a marked increase in
that of acetyl carnitine. Albeit being speculative, the reduced
urinary excretion of free carnitine in the starved subjects may
be indicative of a PPARα-induced increase in the tubular
reabsorption of carnitine in the kidney which is possibly
mediated by an upregulation of OCTN2. In another study
with human subjects, from which skeletal muscle biopsies
were taken, no change in skeletal muscle carnitine levels
were found in patients under starvation conditions [87].
This finding however does not argue against the hypothesis
that PPARα is a regulator of carnitine homeostasis also
in humans because the carnitine concentration in skeletal
muscle, which is the main storage site for carnitine in the
body, is expected to change only slightly even if OCTN2
is upregulated by PPARα activation. Supportive of this
assumption is the observation that concentrations of total
carnitine in skeletal muscle also did not change in rats and
pigs which were starved for 24 h [48, 67]. Further indications
with regard to the regulation of carnitine homeostasis by
PPARα in humans may be expected to be obtained from
clinical studies dealing with pharmacological PPARα agonists
(i.e., fibrates). However, according to our literature research
no clinical studies investigating the eﬃcacy of diﬀerent
fibrates (gemfibrozil, bezafibrate, fenofibrate, etiofibrate,
ciprofibrate) for blood lipid modifying purposes were found
that also reported on either plasma or urinary carnitine
levels.
5. Evidence for a Role of Other PPAR Isotypes in
Regulating Genes Involved in
Carnitine Homeostasis
Besides PPARα, two other PPAR isotypes, PPARγ, which
is expressed in two diﬀerent full-length translated isoforms
(PPARγ1, PPARγ2), and PPARδ, exist inmammals and birds.
The distribution pattern and expression levels of the PPARs
show great diﬀerences between tissues. Whereas PPARα is
highly expressed in tissues with high rates of fatty acid oxi-
dation (liver, kidney, myocardium, skeletal muscle), PPARγ1
is poorly expressed in these tissues. Both PPARα and PPARγ1
are found in cells of the immune system and the vessel
wall and in epithelial cells. The adipocyte-specific PPARγ2
isoform is exclusively and highly expressed in adipose tissue.
PPARδ is ubiquitously expressed and the predominant PPAR
isotype in skeletal muscle. To our knowledge only one
study has been published investigating the role of other
PPAR isotypes than PPARα on genes involved in either
carnitine uptake or carnitine biosynthesis [88]. According
to this study the expression of OCTN2 in the colon is
upregulated by PPARγ in humans and mice and thereby
contributes to local and systemic carnitine homeostasis.
Whether PPARγ is also a transcriptional regulator of genes
encoding enzymes of the carnitine biosynthesis pathway has
not been investigated in this study. In addition, the role of
PPARδ in regulating genes involved in carnitine homeostasis
has not been addressed so far. However, PPARδ has similar
and partially overlapping functions as PPARα, in particular
with regard to fatty acid catabolism [89]. For instance,
genes encoding proteins of the carnitine shuttle system,
such as carnitine-palmitoyltransferase I [90] and carnitine-
acylcanitine translocase [91], were shown to be regulated
by both PPARα and PPARδ. Thus, it would be not unlikely
that PPARδ is also a transcriptional regulator of OCTN2 and
genes of the carnitine biosynthesis pathway. This, however,
remains to be shown in future studies.
6. Conclusions
Comparison of data from genetic and animal studies with
mice, rats, pigs, cows, and laying hens and from human
studies on the regulation of genes involved in carnitine
homeostasis by PPARα suggests that carnitine homeostasis,
which is intrinsically linked with lipid catabolism, is well
conserved across diﬀerent species. This confirms recent
observations from genome-wide comparative analysis of
gene regulation by PPARα between mouse and human
demonstrating that at least the role of PPARα as a master
regulator of hepatic lipid catabolism is well conserved [20].
However, despite demonstrating a well conserved role of
PPARα as a key regulator of carnitine homeostasis in general,
our comprehensive analysis shows that this assumption
particularly applies to the regulation of genes involved in car-
nitine uptake (OCTN2) by PPARα which is obviously highly
conserved across species. The highly conserved regulation
of OCTN2 by PPARα is possibly explained by the fact that
the sequence of the functional PPRE identified in the mouse
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OCTN2-PPREint1 gt
OCTN2-PPREint1 gt
OCTN2-PPREint1 gt
OCTN2-PPREint1 gt
OCTN2-PPREint1 gt
OCTN2-PPREint1 ge
ag 2261–2293
ag 1840–1872
ag 2009–2041
ag 2319–2351
ag 1707–1739
ag 2143–2175
H. sapiens
M. musculus
R. norvegicus
S. scrofa
B. taurus
G. gallus
TGACCTtTGACCT
ACTGGAaACTGGA
AGGAGTTATGTGCCCTtTCACCTACTTATATGT
AAGAGTTATATGCCCTtTCACCTACTTACAGGT
GAGAGTTATATGCCCTtTCACCTACTTACAGGT
ACGAGTTGTGTGCCCTtTCACCTACTTACAGGT
AAGAGCTCTGTGCCCTtTCACCTACTTCCAGGT
GAAGCTTACCTGAACTtTGCACTGCAGTGCACT
cons. PPRE
∗ ∗ ∗ ∗∗∗∗∗∗∗ ∗∗
Figure 1: Sequence alignment of the functional PPRE in the intron 1 of human, mouse, rat, pig, cattle, and chicken OCTN2. The PPRE,
which is comprised of two hexanucleotides separated by a single nucleotide, termed direct repeat 1, is underlined. Matching nucleotides
are shown by asterisks. Chromosomal localization, accession number of cDNA, and genomic DNA sequences from Genbank of NCBI are:
hOCTN2 chr.5, AF057164 cDNA, AC118464 genomic DNA; mOCTN2 chr.11, BC031118 cDNA, AL596182 genomic DNA; rOCTN2 chr.10,
NM 019269 cDNA, AC120085 genomic DNA; sOCTN2 chr.2, AK393575/AK394838/FS677719 cDNA, CU372899 genomic DNA; cOCTN2
chr.7, NM 001046502 cDNA, AC149665 genomic DNA; chOCTN2 chr.13, NM 001045828 cDNA, JH374679 genomic DNA.
H. sapiens
M. musculus
R. norvegicus
B. taurus
G. gallus
BBOX1-PPREint2 gt
BBOX1-PPREpro
BBOX1-PPREint1 gt
BBOX1-PPREint1 gt
BBOX1-PPREint1 gt
TACTCTCACCAGAACAaAGGTCCCAGCGTCAAT
TACTCTAATCAGAACAaAGGTCCCGGCATGGGG
TGCTCTAAGCAGAACAaAGGTCCCAGCGTTGGT
TACTCTCATCAGAACAaAGGTCCCAGCACAGAT
TAAATGCTCTGGAATGaAGGTCAACCTTAAAAA
ag 13752−13784
−65–−101
ag 1307–1339
ag 9997–10029
ag 2002–2034
AGGTCAaAGGTCA
TCCAGTtTCCAGT
cons. PPRE
∗ ∗∗∗ ∗∗∗∗∗∗
Figure 2: Sequence alignment of the functional PPRE in the promoters, intron 1 and intron 2, respectively, of human, mouse, rat, pig,
cattle, and chicken BBOX1. The PPRE, which is comprised of two hexanucleotides separated by a single nucleotide, termed direct repeat
1, is underlined. Matching nucleotides are shown by asterisks. The BBOX1-PPRE for S. scrofa is not shown due to gaps in the first
and second intron. Chromosomal localization, accession number of cDNA, and genomic DNA sequences from Genbank of NCBI are:
hBBOX1 chr.11, NM 003986 cDNA, AC015756 genomic DNA; mBBOX1 chr.2, NM 130452 cDNA, AL691416 genomic DNA; rBBOX1
chr.3, NM 022629/FQ210746 cDNA, AABR03024937 genomic DNA; cBBOX1 chr.15, NM 001101881 cDNA, genomic DNA; sBBOX1 chr.2,
AK393528/AK391112 cDNA. CU694591 genomic DNA; chBBOX1 Chr.5, BX936048 cDNA, JH374511 genomic DNA.
CCTGACACTTTTTCCTgTGGCCTTTGCTCTTCG
TGGAACTGGAAGACCTtTGGCCTAGATAATTAC
GAGGGCTAGAAGCCCTcTGGCCTAGCGGAGAGC
ATCGGAGCTGTAGCCAcTGGCCTATGCCAGAGC
CTTTTCTCCTTTGCCTtTCGCCTCTCTTCTTTT
CAAATGCTGCTGCCCTaAGCCCTCAGGCAATAA
−1029–−1068
−122–−154
−381–−413
−3153–−3185
−4778–−4810
−1050–−1082
H. sapiens
M. musculus
R. norvegicus
S. scrofa
B. taurus
G. gallus
ALDH9A1-PPRE
ALDH9A1-PPRE
ALDH9A1-PPRE
ALDH9A1-PPRE
ALDH9A1-PPRE
ALDH9A1-PPRE
cons. PPRE TGACCTtTGACCT
ACTGGAaACTGGA
∗∗ ∗∗∗
Figure 3: Sequence alignment of the functional PPRE in the promoter of human, mouse, rat, pig, cattle, and chicken ALDH9A1. The PPRE,
which is comprised of two hexanucleotides separated by a single nucleotide, termed direct repeat 1, is underlined. Matching nucleotides
are shown by asterisks. Chromosomal localization, accession number of cDNA, and genomic DNA sequences from Genbank of NCBI
are: hALDH9A1 chr.1, AK392520 cDNA, AL451074, genomic DNA; mALDH9A1 chr.1, NM 019993, cDNA, AC113970 genomic DNA;
rALDH9A1 chr.13, NM 022273 cDNA, AABR06075994 genomic DNA; sALDH9A1 chr.4, AK392520 cDNA, CU468388 genomic DNA;
cALDH9A1 chr.3, BC105335 cDNA, AAFC03093575 genomic DNA; chALDH9A1 Chr.8, BU460904 cDNA, JH374592 genomic DNA.
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OCTN2 gene is completely identical (100%) between mouse,
rat, pig, cattle, and even human (Figure 1). The comparison
of studies in pigs with studies in mice and rats, however,
shows that the upregulation of OCTN2 in the liver by
PPARα activation is clearly stronger in rodents than in pigs,
which is in line with the view that nonproliferating species
(pig, human, nonhuman primates) generally show a weaker
response to PPARα activation than proliferating species
(mice, rats). In contrast, regulation of genes involved in car-
nitine biosynthesis (BBOX1, ALDH9A1) by PPARα appears
less well conserved across species, which is demonstrated by
the fact that PPARα activation causes upregulation of genes
involved in carnitine biosynthesis in mice, pigs and cattle
but not in rats and chicken. The reasons underlying these
species specificities cannot be simply explained by diﬀerences
in the PPARα expression level between species because mice
and rats, for instance, exhibit comparably high hepatic
PPARα expression levels. In the case of BBOX1 diﬀerences
in the nucleotide sequence of the functional PPRE of the
BBOX1 gene between mouse and rat also cannot explain
this species specificity because this PPRE shares a complete
(100%) sequence identity between mouse and rat and even
human and cattle (Figure 2). One factor that may account
for the species specificity regarding BBOX1 regulation by
PPARα is the diﬀerent location of the translation start
site of the BBOX1 gene between mouse (translation start
site in the first exon) and rat (translation start site in
the second exon). In addition, a species specific expression
pattern of transcriptional coregulators in the liver may be
causative for the diﬀerent regulation of BBOX1 by PPARα
between mouse and rat. By contrast, a small discrepancy
in the sequence of the functional PPRE of the ALDH9A1
promoter between mouse and rat (one nucleotide in the
proximal half site of the PPRE is diﬀerent) could explain the
species specificity regarding ALDH9A1 regulation by PPARα
(Figure 3). Nevertheless, multiple factors may be respon-
sible for the diﬀerent regulation of carnitine biosynthesis
by PPARα across diﬀerent species and, therefore, further
research is required to unravel the underlying reasons.
Overall, our comparative analysis indicates that PPARα is
not only a master transcriptional regulator of fatty acid
catabolism, ketogenesis, and gluconeogenesis but also of
carnitine homeostasis—a role which is well conserved across
species.
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